Effect of Human Central Nervous System Stem Cell Subretinal Transplantation on Progression of Geographic Atrophy Secondary to Nonneovascular Age-Related Macular Degeneration.

Purpose: To evaluate the effect of subretinally transplanted human central nervous system stem cells (HuCNS-SC) on the progression of geographic atrophy (GA) in patients with nonneovascular age-related macular degeneration (AMD).

Design: Multicenter, prospective, phase 1 open-label clinical trial.

Participants: Fifteen patients with bilateral GA solely the result of AMD.

Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study.

Background: The purpose of this study is to evaluate the ocular tolerability and efficacy of sirolimus administered as subconjunctival or intravitreal injections in patients with non-infectious uveitis. Sirolimus as a Therapeutic Approach for Uveitis (SAVE) is a prospective, randomized, open-label, interventional study. Thirty patients were enrolled and randomized in 1:1 ratio to receive either intravitreal injections of 352 μg sirolimus or subconjunctival injections of 1,320 μg at days 0, 60, and 120, with primary endpoint at month 6.

Tolerability and pharmacokinetics of intravitreal sirolimus.

Purpose: To evaluate the pharmacokinetics (PK) and tolerability of a proprietary sirolimus depot-forming ocular formulation in rabbits and humans after a single intravitreal (i.v.t.

A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema.

Objective: To evaluate the safety and tolerability of a single subconjunctival (SCJ) or intravitreal (IVT) injection of an ophthalmic sirolimus formulation in eyes with diabetic macular edema (DME).

Design: Randomized, open-label, dose-escalating phase I study.

Participants: Fifty eyes among 50 patients with DME, retinal thickness ≥ 300 microns and best-corrected visual acuity (BCVA) 20/40 to 20/200.

Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.

Objective: To compare the treatment effect and safety of photodynamic therapy with verteporfin using a standard (SF) or reduced (RF) light fluence rate with that of placebo therapy in patients with subfoveal minimally classic choroidal neovascularization (CNV) with age-related macular degeneration.

Design: Phase 2, multicenter, double-masked, placebo-controlled, randomized clinical trial.

Setting: Nineteen ophthalmology practices in North America and Europe.

Correlation between corneal sensitivity, subjective dry eye symptoms and corneal staining in Sjögren's syndrome.

Background: Previous studies have shown a poor correlation between dry eye symptoms and objective clinical signs in patients with Sjögren's syndrome. We examined the hypothesis that reduced corneal sensitivity is associated with increased ocular surface disease and reduced symptoms in patients with Sjögren's syndrome.

Methods: Eighteen subjects with a diagnosis of Sjögren's syndrome attending a Sjögren's clinic participated in the study.

Outcomes of repeat penetrating keratoplasty and risk factors for graft failure.

Purpose: To compare repeat penetrating keratoplasty (PKP) with primary PKP with respect to patient characteristics, survival rates, and risk factors for graft failure.

Methods: Retrospective, consecutive, noncomparative case series of 116 patients who underwent repeat PKP and who were identified from a cohort of 696 PKPs performed by one surgeon over a 7.5-year period.

The role of epithelial defects in intralamellar inflammation after laser in situ keratomileusis.

Background: A single factor responsible for diffuse lamellar keratitis (DLK) after laser in situ keratomileusis (LASIK) has not yet been identified. Various theories have been proposed to explain what may trigger this condition. We evaluated the role of epithelial defects in interface inflammation and assessed the outcome of eyes with DLK with and without epithelial defects.

A randomized, double-masked clinical trial of Optisol-GS vs Chen Medium for human corneal storage.

Objective: To determine whether the clinical outcome of corneal transplantation performed with tissue stored in Chen Medium (CM; Chen Laboratories, Phoenix, Md) is superior to that of Optisol-GS (Chiron Ophthalmics, Irvine, Calif).

Design: Randomized, double-masked trial.

Participants And Setting: Ninety patients undergoing corneal transplantation at a tertiary center.